Mirvaso Evrópusambandið - íslenska - EMA (European Medicines Agency)

mirvaso

galderma international - brimonidintartrat - húðsjúkdómar - aðrar húðsjúkdómar - mirvaso er ætlað til meðferðar við geðrofsroði rósroða hjá fullorðnum sjúklingum.

Metvix Krem 160 mg/g Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

metvix krem 160 mg/g

galderma nordic ab - methyl aminolevulinate hydrochloride - krem - 160 mg/g

Differin Hlaup 1 mg/g Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

differin hlaup 1 mg/g

galderma nordic ab - adapalenum inn - hlaup - 1 mg/g

Soolantra Krem 10 mg/g Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

soolantra krem 10 mg/g

galderma nordic ab - ivermectinum inn - krem - 10 mg/g

Epiduo Hlaup 0,1 % / 2,5 % Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

epiduo hlaup 0,1 % / 2,5 %

galderma nordic ab - adapalenum inn; benzoylis peroxidum - hlaup - 0,1 % / 2,5 %

Aklief Krem 50 míkróg/g Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

aklief krem 50 míkróg/g

galderma nordic ab - trifarotenum - krem - 50 míkróg/g

Oracea Hart hylki með breyttan losunarhraða 40 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

oracea hart hylki með breyttan losunarhraða 40 mg

galderma nordic ab - doxycyclinum inn - hart hylki með breyttan losunarhraða - 40 mg

Vegzelma Evrópusambandið - íslenska - EMA (European Medicines Agency)

vegzelma

celltrion healthcare hungary kft. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - Æxlishemjandi lyf - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. sjá nánar í kafla 5 til að fá nánari upplýsingar varðandi húðþéttni vaxtarþáttar viðtaka 2 (her2). vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. nánari upplýsingar um her2 stöðu, sjá kafla 5. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Giotrif Evrópusambandið - íslenska - EMA (European Medicines Agency)

giotrif

boehringer ingelheim international gmbh - afatinib - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - giotrif eitt og sér er ætlað fyrir meðferð ofepidermal vöxt Þáttur viðtaka (egfr) tki-barnalegt fullorðinn sjúklinga með staðnum háþróaður eða sjúklingum ekki lítið klefi lungnakrabbamein (nsclc) með því að virkja egfr stökkbreytingu(s);staðnum háþróaður eða sjúklingum nsclc af æxli vefjasýni gengur á eða eftir platínu-byggt lyfjameðferð.

Rybrevant Evrópusambandið - íslenska - EMA (European Medicines Agency)

rybrevant

janssen-cilag international n.v.    - amivantamab - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.